Research programme: RNAi-based influenza therapeutics - Alnylam/Arrowhead Pharmaceuticals

Drug Profile

Research programme: RNAi-based influenza therapeutics - Alnylam/Arrowhead Pharmaceuticals

Alternative Names: ALN-FLU01; Pandemic influenza therapy - Alnylam/Arrowhead; Short-interfering RNA-based influenza therapies - Alnylam/Arrowhead

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals; Novartis; University of Georgia
  • Developer Alnylam Pharmaceuticals; Arrowhead Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza A virus H5N1 subtype; Influenza virus infections

Most Recent Events

  • 13 Apr 2016 Arrowhead Research Corporation is now called Arrowhead Pharmaceuticals
  • 09 Mar 2015 Arrowhead acquires RNAi research and development portfolio from Novartis
  • 14 Jul 2010 Preclinical development is ongoing in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top